Panelists discuss how quadruplet therapy has become the new benchmark for NDMM, offering deeper and more durable responses than previous triplet regimens.
Expert Perspectives on Novel Combination Therapy in Newly Diagnosed Myeloma
Panelists discuss how risk stratification using cytogenetic and molecular markers is vital to tailoring NDMM therapy and improving long-term outcomes.
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
3
Classifying High-Risk Patients With NDMM
4
Unraveling the Complexities of Proximal-Type Epithelioid Sarcoma of the Vulva
5
